Cite
Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol
MLA
Lars Bauer, et al. “Predictors of Long-Term Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol.” Arthritis Research & Therapy, vol. 23, Oct. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....91e0b697c7ea83bd04f77aace0705989&authtype=sso&custid=ns315887.
APA
Lars Bauer, Bengt Hoepken, Martin Rudwaleit, Simone E. Auteri, Walter P. Maksymowych, & Thomas Kumke. (2021). Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol. Arthritis Research & Therapy, 23.
Chicago
Lars Bauer, Bengt Hoepken, Martin Rudwaleit, Simone E. Auteri, Walter P. Maksymowych, and Thomas Kumke. 2021. “Predictors of Long-Term Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol.” Arthritis Research & Therapy 23 (October). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....91e0b697c7ea83bd04f77aace0705989&authtype=sso&custid=ns315887.